NEUROONE (NMTC) Insider Sale — 906 Shares Disposed at $0.8886

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES (NMTC) Chief Technology Officer Steve Mertens reported a sale of 906 shares of common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 161,329 shares, held directly. The Form 4 was signed by an authorized representative on 10/01/2025.

Positive

• Transaction was disclosed via Form 4, showing compliance with Section 16 reporting requirements
• Post-transaction beneficial ownership is explicitly reported as 161,329 shares (direct)

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sale of 906 shares is disclosed; transaction size appears immaterial relative to typical outstanding shares.

The Form 4 reports a routine disposition by the CTO on 09/30/2025 at $0.8886 per share, leaving 161,329 shares beneficially owned. This is a straightforward, single-day sale reported via the required SEC disclosure process. There is no additional context in the filing about purpose or related-party arrangements, and no derivative holdings were reported.

Corporate Governance Expert

TL;DR: Timely Form 4 filing shows compliance with Section 16 reporting; no governance red flags in this single disclosure.

The report was executed by a power of attorney and signed on 10/01/2025, consistent with procedural practices. The filing lists the reporting person as an officer (CTO) and shows direct ownership only. There are no indications of coordinated group filings or unusual transactions disclosed in this document.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mertens Steve

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	906	$0.8886	$805.07

Holdings After Transaction: Common Stock — 161,329 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mertens Steve

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F		906	D	$0.8886	161,329	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the NMTC reporting person make?

The CTO, Steve Mertens, sold 906 shares of NMTC common stock on 09/30/2025 at a reported price of $0.8886 per share.

How many NMTC shares does the reporting person own after the transaction?

After the reported sale, the reporting person beneficially owns 161,329 shares, held directly.

When was the Form 4 filed and signed for the NMTC transaction?

The Form 4 shows the transaction date as 09/30/2025 and the signature by power of attorney dated 10/01/2025.

Were any derivative securities (options, warrants) reported in this filing for NMTC?

No derivative securities were reported in Table II of this Form 4; only a non-derivative sale of common stock is listed.

What is the reporting person's role at NMTC according to the filing?

The reporting person is identified as an Officer with the title Chief Technology Officer and also listed as a Director.